OptiBiotix Health PLC OptiBiotix Capital Reorganisation (1412G)
February 28 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1412G
OptiBiotix Health PLC
28 February 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
OptiBiotix Capital Reorganisation
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
announced on 28 November 2017 that it intended to seek a
cancellation of its share premium account (the "Capital Reduction")
in order to create distributable reserves to allow the Company to
make future dividend payments.
OptiBiotix is pleased to announce that, following shareholder
approval which was granted on 25 January 2018, the High Court of
Justice made an order confirming the Capital Reduction on 27
February 2018.
Following the registration of the Court order confirming the
Capital Reduction by the Registrar of Companies in England and
Wales, the Capital Reduction became effective 27 February 2018.
Stephen O'Hara, CEO of OptiBiotix, commented: "I am pleased to
report that both shareholders and the Courts have confirmed the
capital reduction. This allows OptiBiotix to make future dividend
or 'dividend in specie' distributions to the Company's shareholders
should it be appropriate to do so. This is part of OptiBiotix's
strategy of building value across its divisions and where possible
releasing value back to shareholders."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTRMFTMBITBAP
(END) Dow Jones Newswires
February 28, 2018 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024